Parkinson's Disease Market is segmented By Type (Juvenile Parkinson Disease, Young-Onset Parkinson’s Disease, Idiopathic Parkinson Disease), By Age (Adult, Pediatric), By Diagnosis(CT Scan, MRI Scan, DaTSCAN-SPECT scan, PET Scan), By Drug Class (Carbidopa-Levodopa, Carbidopa-Levodopa Infusion, Dopamine Agonists, Monoamine Oxidase B Inhibitors, Catechol O-Methyltransferase Inhibitors, Anticholinergics, Amantadine), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) – Share, Size, Outlook, And Opportunity Analysis, 2023-2030.
The Dementia Drugs Market size was valued at $8.7 billion in 2023, and is projected to reach $19.7 billion by 2030, growing at a CAGR of 8.5% from 2022 to 2030.Dementia causes a decline in mental function from a previously higher level that is severe enough to interfere with daily life.
The global market for complex regional pain syndrome (CRPS) is estimated to be worth US$ 101.9 Million in 2023, rising to US$ 126.7 Million by 2030. During the projection period of 2023 to 2030, the market is forecast to grow at a CAGR of 2.2%.The increase in the number of people suffering from the complex regional pain syndrome (CRPS), chronic pain and back failure syndrome is one of the major reasons for the development of the market.
The global Opioid Use Disorder (OUD) Market size was valued at USD 2.88 billion in 2023 and is projected to grow from USD 3.11 billion in 2022 to USD 5.64 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period. Based on our analysis, the global market exhibited a decline of -10.1% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with opioid use disorder experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.
Global Neuropathic Pain Market From 2023 to 2030, the worldwide neuropathic pain market is predicted to increase at a CAGR of 9.2%. The market is being pushed by the rising prevalence of chronic pain and neuropathic pain syndromes linked to a variety of illnesses. Neuropathic pain is caused by a somatosensory system lesion or illness and affects 7-10% of the general population. Multiple causes of neuropathic pain have been identified, and its prevalence is expected to rise due to an ageing global population, an increase in diabetes mellitus, and improved cancer survival following treatment.
Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!
One of our marquee services We profile relevant start-up companies in the market.
Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.
Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.